Barry Investment Advisors LLC Has $692,000 Holdings in GSK plc (NYSE:GSK)

Barry Investment Advisors LLC boosted its holdings in shares of GSK plc (NYSE:GSK) by 9.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,461 shares of the pharmaceutical company’s stock after buying an additional 1,741 shares during the quarter. Barry Investment Advisors LLC’s holdings in GSK were worth $692,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in GSK. FMR LLC boosted its stake in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after buying an additional 2,224,345 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in GSK during the second quarter valued at $52,487,000. Fisher Asset Management LLC boosted its position in GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after acquiring an additional 870,449 shares during the last quarter. Hotchkis & Wiley Capital Management LLC boosted its position in shares of GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after purchasing an additional 833,080 shares in the last quarter. Finally, Bridgewater Associates LP lifted its position in GSK by 107.3% in the 3rd quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock valued at $39,483,000 after acquiring an additional 500,010 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

NYSE:GSK opened at $35.12 on Wednesday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The company has a fifty day moving average of $33.94 and a two-hundred day moving average of $37.78. The stock has a market capitalization of $72.78 billion, a PE ratio of 22.80, a P/E/G ratio of 1.31 and a beta of 0.63. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on GSK shares. StockNews.com lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Six investment analysts have rated the stock with a hold rating, one has given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.